HC Wainwright Reaffirms “Buy” Rating for Celldex Therapeutics, Inc. (CLDX)

HC Wainwright reaffirmed their buy rating on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in a research report report published on Wednesday morning. They currently have a $6.00 price target on the biopharmaceutical company’s stock.

Separately, Zacks Investment Research downgraded Celldex Therapeutics from a buy rating to a hold rating in a research report on Wednesday, November 16th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $7.63.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX) opened at 3.37 on Wednesday. Celldex Therapeutics has a 52-week low of $2.85 and a 52-week high of $5.13. The stock’s 50 day moving average price is $3.43 and its 200 day moving average price is $3.66. The firm’s market capitalization is $415.23 million.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Tuesday, March 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.04. Celldex Therapeutics had a negative return on equity of 51.46% and a negative net margin of 1,923.41%. The business earned $1.87 million during the quarter, compared to the consensus estimate of $1.10 million. During the same period in the prior year, the company earned ($0.33) EPS. Celldex Therapeutics’s revenue for the quarter was up 4.5% on a year-over-year basis. On average, equities analysts anticipate that Celldex Therapeutics will post ($1.23) earnings per share for the current fiscal year.

Your IP Address:

A number of institutional investors have recently bought and sold shares of CLDX. Virginia Retirement Systems ET AL purchased a new position in Celldex Therapeutics during the third quarter valued at approximately $150,000. Pacad Investment Ltd. purchased a new position in Celldex Therapeutics during the fourth quarter valued at approximately $146,000. Tudor Investment Corp Et Al increased its position in Celldex Therapeutics by 256.6% in the fourth quarter. Tudor Investment Corp Et Al now owns 47,806 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 34,400 shares in the last quarter. Creative Planning increased its position in Celldex Therapeutics by 971.4% in the third quarter. Creative Planning now owns 55,346 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 50,180 shares in the last quarter. Finally, Paulson & CO. Inc. purchased a new position in Celldex Therapeutics during the fourth quarter valued at approximately $251,000. Hedge funds and other institutional investors own 55.99% of the company’s stock.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

5 Day Chart for NASDAQ:CLDX

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2024361/hc-wainwright-reaffirms-buy-rating-for-celldex-therapeutics-inc-cldx.html

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.